Myelofibrosis Complications: What You Need to Know

Why Does Myelofibrosis Cause Complications?

Myelofibrosis is a type of myeloproliferative neoplasm, or MPN. It may develop as primary myelofibrosis or after another MPN, usually polycythemia vera or essential thrombocythemia.

The disease starts when an abnormal blood-forming stem cell produces copies of itself. Many patients have acquired changes involving the JAK2, CALR, or MPL genes. These mutations are generally not inherited from a parent. They contribute to excessive cell signaling, inflammation, abnormal blood-cell production, and the gradual buildup of fibrous scar tissue inside the bone marrow.

As the marrow becomes less effective, it struggles to make healthy red blood cells, white blood cells, and platelets. The body may then try to move blood-cell production to the spleen, liver, or other tissues. It is an impressively resourceful backup plan, but unfortunately not a very tidy one.

Together, abnormal blood cells, marrow scarring, chronic inflammation, and blood production outside the marrow create most myelofibrosis complications.

1. Anemia and Severe Fatigue

Anemia is one of the most common complications of myelofibrosis. It occurs when the body does not have enough healthy red blood cells or hemoglobin to carry oxygen efficiently. Marrow scarring can reduce red-cell production, while an enlarged spleen may trap or destroy circulating blood cells.

Possible anemia symptoms

• Persistent fatigue or weakness
• Shortness of breath during ordinary activities
• Dizziness or lightheadedness
• Headaches
• Pale skin
• Rapid heartbeat or heart palpitations
• Difficulty concentrating

Fatigue related to myelofibrosis is not the ordinary “I stayed up too late watching television” variety. It can make showering, preparing food, climbing stairs, or holding a conversation feel like an athletic event.

Doctors usually investigate whether anemia is caused entirely by myelofibrosis or worsened by bleeding, iron deficiency, low vitamin B12, folate deficiency, kidney problems, or treatment side effects. Management may include red blood cell transfusions, erythropoiesis-stimulating medicines in selected patients, anemia-directed therapies, or adjustments to the patient’s myelofibrosis treatment.

Some people eventually become transfusion-dependent, meaning they need repeated transfusions to maintain safer hemoglobin levels and control symptoms. Transfusions can be extremely helpful, although long-term use may require monitoring for iron overload and other complications.

2. Low Platelet Counts and Bleeding

Platelets help blood clot after an injury. Myelofibrosis can cause thrombocytopenia, or a low platelet count, when scarred marrow cannot produce enough platelets or an enlarged spleen traps too many of them. Platelets may also function abnormally even when the laboratory count does not look dramatically low.

Signs of a bleeding problem

• Bruising after minor bumps
• Frequent nosebleeds
• Bleeding gums
• Tiny red or purple spots on the skin
• Blood in the urine
• Black or bloody stools
• Bleeding that takes unusually long to stop

Severe bleeding is less common but can be dangerous. Gastrointestinal bleeding, heavy internal bleeding, or bleeding in the brain requires immediate medical treatment.

Patients should not automatically take aspirin, ibuprofen, naproxen, herbal blood thinners, or dietary supplements marketed as “circulation boosters.” In myelofibrosis, the decision to use an antiplatelet or anticoagulant drug depends on platelet levels, previous blood clots, bleeding history, other medications, and overall risk.

3. Abnormal White Blood Cells and Infection Risk

Myelofibrosis may cause white blood cell counts to be too high, too low, or filled with cells that do not work normally. A low neutrophil count can weaken the body’s ability to fight bacteria and fungi. Treatments that suppress blood-cell production may add to that risk.

Symptoms that may signal an infection

• Fever or chills
• New cough or shortness of breath
• Burning or pain during urination
• Persistent diarrhea
• Redness, warmth, drainage, or swelling around a wound
• New confusion or extreme weakness

A fever that might be “just a bug” in someone else can be more urgent in a person with low white blood cells. Patients should ask their hematology team what temperature requires an immediate call, because the recommended threshold may depend on their counts, medications, and treatment history.

Preventive care may include recommended vaccinations, careful hand hygiene, food-safety precautions, and early evaluation of infections. Patients should discuss live vaccines with their medical team rather than assuming every vaccine is appropriate during treatment.

4. An Enlarged Spleen

When the marrow cannot keep up with blood-cell production, the spleen may begin producing blood cells through a process called extramedullary hematopoiesis. The extra workload can cause substantial spleen enlargement, known as splenomegaly.

How splenomegaly may feel

• Pressure or pain beneath the left rib cage
• A feeling of abdominal heaviness
• Feeling full after only a few bites
• Reduced appetite
• Unintentional weight loss
• Discomfort when bending or sleeping in certain positions

A large spleen may also trap red blood cells and platelets, worsening anemia and thrombocytopenia. In rare situations, a very enlarged spleen can become injured or rupture. Sudden severe pain in the upper left abdomen, especially with pain that travels to the left shoulder, dizziness, fainting, or rapid heartbeat, should be treated as an emergency.

JAK inhibitors are commonly used to reduce spleen size and improve symptoms. Less commonly, doctors may consider radiation to the spleen or surgical removal. Splenectomy can relieve selected cases but carries meaningful risks, including bleeding, infection, and blood clots, so it is not a casual “let’s just take it out” decision.

5. Liver Enlargement and Portal Hypertension

The liver may also take on blood-cell production and become enlarged. Increased blood flow from a large spleen, blood clots in abdominal veins, or blood-forming tissue around the liver can raise pressure in the portal vein. This condition is called portal hypertension.

Portal hypertension can enlarge veins in the esophagus or stomach. These fragile veins, called varices, may rupture and cause serious bleeding.

Seek urgent care for possible gastrointestinal bleeding

• Vomiting blood or material resembling coffee grounds
• Black, tar-like stool
• Bright red blood in the stool
• Sudden weakness, fainting, or confusion
• Rapid heart rate with abdominal symptoms

Patients with abdominal swelling, worsening liver-test results, or suspected portal hypertension may need imaging, evaluation by a liver specialist, or endoscopy to look for enlarged veins.

6. Blood Clots

Although thrombosis is generally more prominent in polycythemia vera and essential thrombocythemia, people with myelofibrosis can also develop abnormal blood clots. Risk may be influenced by blood counts, inflammation, previous clots, age, cardiovascular health, genetic features, mobility, and treatment.

A clot may occur in a deep leg vein, the lungs, brain, heart, or abdominal blood vessels. Symptoms such as one-sided weakness, facial drooping, difficulty speaking, chest pain, sudden shortness of breath, coughing blood, or painful swelling in one leg require emergency care.

The awkward truth is that myelofibrosis can increase both clotting and bleeding risks. This is why treatment decisions must be individualized rather than based on the cheerful but incorrect idea that every blood problem can be fixed with a daily aspirin.

7. Blood-Forming Tissue Outside the Marrow

Extramedullary hematopoiesis usually affects the spleen and liver, but blood-forming tissue may occasionally develop in other locations. These growths are not typical solid tumors, but their location can create serious problems.

Depending on where the tissue forms, complications may include gastrointestinal bleeding, coughing blood, fluid around the lungs, nerve compression, seizures, or spinal cord compression.

New leg weakness, numbness, loss of bladder control, severe back pain, seizures, or sudden neurological symptoms should be evaluated urgently. Imaging is often needed to determine whether a mass, bleeding, infection, or another condition is responsible.

8. Inflammation, Weight Loss, and Constitutional Symptoms

Myelofibrosis can trigger ongoing inflammatory signaling. The result may be drenching night sweats, low-grade fever, itching, bone pain, loss of appetite, brain fog, and unintended weight loss.

These are sometimes called constitutional symptoms because they affect the whole body rather than one organ. They can contribute to muscle loss, poor nutrition, sleep disruption, emotional distress, and declining physical function.

Patients should report worsening weight loss or reduced food intake early. Small frequent meals, calorie-dense snacks, nutritional drinks, symptom treatment, and consultation with an oncology dietitian may help. Treating an enlarged spleen can also make eating easier by giving the stomach more room to do its job.

9. Progression to Acute Myeloid Leukemia

Some cases of myelofibrosis progress to acute myeloid leukemia, or AML. This transformation does not happen to everyone, but it is one of the most serious potential complications.

Possible warning signs include rapidly worsening anemia, falling platelet levels, increasing blast cells in the blood or marrow, frequent infections, new bleeding, persistent fever, worsening bone pain, and a sudden decline in overall health.

Doctors estimate progression risk by considering age, symptoms, blood counts, chromosome findings, gene mutations, transfusion needs, and the percentage of immature cells in the blood. Risk-scoring systems do not predict a person’s future with perfect accuracy, but they help guide decisions about monitoring, treatment, clinical trials, and stem cell transplantation.

How Doctors Monitor Myelofibrosis Complications

Monitoring is not simply waiting for something bad to happen. It is an active strategy designed to spot changes before they become emergencies.

A follow-up plan may include

• Complete blood counts and review of blood-cell appearance
• Physical examination of the spleen and liver
• Questions about fatigue, pain, appetite, night sweats, and weight
• Blood chemistry and organ-function testing
• Ultrasound, CT, or MRI when organ enlargement is uncertain
• Repeat bone marrow testing when disease progression is suspected
• Molecular and chromosome testing when clinically appropriate
• Review of transfusion frequency and treatment side effects

Keeping a simple symptom log can be surprisingly useful. Record fever, bleeding, infections, abdominal discomfort, appetite changes, weight, activity tolerance, and new medications. The notebook does not need decorative tabs or the organizational discipline of an air-traffic controller. It only needs enough information to reveal patterns.

How Complications May Be Treated

There is no single treatment plan for every patient. Someone with mild, stable disease may need active surveillance, while another person may need treatment for anemia, severe splenomegaly, low platelets, or high-risk disease.

Common management approaches

• Blood transfusions: Used to relieve symptoms of significant anemia.
• Anemia-directed treatment: May include medications that encourage red blood cell production or therapies selected for anemia-dominant disease.
• JAK inhibitors: Ruxolitinib, fedratinib, pacritinib, and momelotinib may reduce spleen enlargement and systemic symptoms. Selection depends partly on anemia, platelet count, previous therapy, and other health factors.
• Supportive care: Includes infection treatment, nutritional support, pain management, mental health care, and rehabilitation.
• Clinical trials: May provide access to new drug combinations or therapies for people with an incomplete response to existing treatment.
• Allogeneic stem cell transplant: The only treatment with curative potential, but it carries substantial risks and is reserved for carefully selected patients.

Treatment may control one complication while affecting another. For example, a medication that reduces spleen size may initially lower hemoglobin or platelets. Careful dose adjustments and repeated laboratory testing are therefore part of treatment, not evidence that the medical team misplaced the instruction manual.

When to Call the Doctor or Seek Emergency Care

Contact the hematology team promptly for

• Increasing fatigue or shortness of breath
• New bruising, nosebleeds, or bleeding gums
• Fever or signs of infection
• Increasing abdominal fullness or spleen pain
• Unexplained weight loss
• New bone pain or night sweats
• Noticeably reduced exercise tolerance
• A sudden change in blood counts

Seek emergency medical help for

• Chest pain or sudden difficulty breathing
• Signs of stroke
• Uncontrolled bleeding
• Vomiting blood or passing black stools
• Fainting or severe dizziness
• Sudden severe pain beneath the left ribs
• New seizures, weakness, numbness, or loss of bladder control

Everyday Experiences With Myelofibrosis Complications

The following situations are illustrative composite examples. They reflect common challenges described by people living with myelofibrosis but are not individual patient histories.

When fatigue quietly changes the daily schedule

A person with worsening anemia may first notice that ordinary activities require more planning. Grocery shopping that once took 30 minutes may require a rest in the parking lot. Laundry might be divided into several smaller jobs. Friends may say, “You look fine,” which is usually intended as encouragement but can feel frustrating when the body seems to be operating on a battery stuck at 18%.

Many patients learn to schedule demanding activities during their best hours of the day. They may sit while preparing meals, use delivery services, accept help with transportation, or take short planned rests before exhaustion becomes overwhelming. This is energy conservation, not laziness. Reporting the change is important because increasing fatigue may signal worsening anemia, disease progression, infection, medication effects, or another treatable condition.

When an enlarged spleen changes eating

Another common experience is feeling full after a surprisingly small amount of food. A patient may prepare a normal dinner, take five bites, and feel as though they have completed a holiday feast. Pressure under the left ribs may make tight clothing uncomfortable or interfere with sleep.

Small meals every few hours may be easier than three large meals. Nutrient-dense foods can provide more protein and calories without requiring a heroic plate of food. Some people track weight weekly so gradual loss does not go unnoticed. When treatment reduces spleen size, appetite and comfort may improve, sometimes making mealtime feel normal again instead of like a negotiation with an overcrowded abdomen.

When laboratory results create emotional whiplash

Living with myelofibrosis can involve long stretches of stable results followed by a confusing change in hemoglobin, platelets, or white blood cells. Patients may begin treating every laboratory report like a final exam. A slightly different number can produce hours of worry before the medical team explains that trends matter more than a single isolated result.

It often helps to ask what changes are expected, which numbers require an urgent call, and what the next decision point will be. Understanding the plan can turn an alarming number into useful information. Caregivers can help by attending appointments, taking notes, managing medication lists, and watching for symptoms the patient may minimize.

When treatment brings trade-offs

A JAK inhibitor may reduce night sweats, spleen discomfort, itching, and weight loss while also affecting blood counts. A transfusion may restore enough energy for daily activities but require repeated clinic visits. A stem cell transplant may offer curative potential while introducing serious short- and long-term risks.

These decisions rarely have a perfect option wrapped in a bow. The best choice depends on disease risk, age, overall health, symptoms, personal priorities, donor availability, and tolerance for uncertainty. Some patients prioritize energy and independence. Others focus on pursuing the strongest disease-directed strategy available. Good care makes room for both medical evidence and the patient’s definition of an acceptable life.

Building a workable routine

People often cope better when they create a routine around blood tests, medications, food, movement, rest, and communication. Gentle activity may help preserve strength, provided the medical team considers it safe. Support groups and counseling can reduce isolation, particularly because myelofibrosis is rare and explaining it repeatedly can become exhausting.

The practical lesson is not to monitor every sensation with panic. It is to understand personal warning signs, report meaningful changes early, and keep appointments even during stable periods. Myelofibrosis may be unpredictable, but informed monitoring gives patients and clinicians more opportunities to respond before a complication takes center stage.

Conclusion

Myelofibrosis complications develop mainly because scarred bone marrow cannot produce healthy blood cells normally and the body begins making blood cells elsewhere. Anemia, low platelets, infections, spleen enlargement, portal hypertension, abnormal bleeding, blood clots, and progression to acute leukemia are among the most important risks.

Not every person will experience every complication. Many problems can be treated or controlled, especially when changes are identified early. Regular blood tests, symptom tracking, prompt attention to warning signs, and care from a hematologist experienced in myeloproliferative neoplasms can make the disease much more manageable.

Medical note: This article is intended for general education and does not replace diagnosis or treatment from a qualified healthcare professional. Patients should never start, stop, or change a myelofibrosis medication, aspirin, anticoagulant, supplement, or transfusion plan without consulting their care team.

Editorial sourcing note: The medical information was synthesized from current patient and professional resources published by the National Cancer Institute, Mayo Clinic, Cleveland Clinic, MD Anderson Cancer Center, Dana-Farber Cancer Institute, MedlinePlus, the Leukemia & Lymphoma Society/Blood Cancer United, the MPN Research Foundation, the American Society of Hematology, the U.S. Food and Drug Administration, SEER, and peer-reviewed literature available through PubMed Central.